MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis

Journal of Clinical Investigation

Volumn 127, Issue 2, 2017, Pages 564-568

  Cai, Bishuang ^a   Thorp, Edward B ^b   Doran, Amanda C ^a   Sansbury, Brian E ^c   Daemen, Mat J A P ^d   Dorweiler, Bernhard ^e   Spite, Matthew ^c   Fredman, Gabrielle ^f   Tabas, Ira ^a,g  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f ALBANY MEDICAL COLLEGE   (United States)

^g NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C MER TYROSINE KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR; MERTK PROTEIN, HUMAN; MERTK PROTEIN, MOUSE; ONCOPROTEIN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; EFFEROCYTOSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NECROSIS; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; ANIMAL; CAROTID ARTERY DISEASE; ENZYMOLOGY; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY;

ANIMALS; CAROTID ARTERY DISEASES; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; NECROSIS; PLAQUE, ATHEROSCLEROTIC; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, LDL;

EID: 85014120850     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI90520     Document Type: Article

References (38)

1. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262-1275.
2. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(6):1256-1261.
3. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25(11):2255-2264.
4. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 2008;22(10):3595-3606.
5. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10(1):36-46.
6. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447(7146):869-874.
7. Mitchell S, et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol. 2002;13(10):2497-2507.
8. Cai B, et al. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc Natl Acad Sci U S A. 2016;113(23):6526-6531.
9. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/-mice. Arterioscler Thromb Vasc Biol. 2008;28(8):1421-1428.
10. Ait-Oufella H, et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(8):1429-1431.
11. Sather S, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 2007;109(3):1026-1033.
12. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem. 2011;286(38):33335-33344.
13. Garbin U, et al. Expansion of necrotic core and shedding of Mertk receptor in human carotid plaques: A role for oxidized polyunsaturated fatty acids? Cardiovasc Res. 2013;97(1):125-133.
14. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93(5):1885-1893.
15. Fredman G, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med. 2015;7(275):275ra20.
16. Krishnamoorthy N, et al. Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation. J Immunol. 2015;194(3):863-867.
17. Gagliani N, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015;523(7559):221-225.
18. Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis. 2013;230(1):92-99.
19. Foks AC, et al. Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis. 2011;218(1):53-60.
20. Fredman G, et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun. 2016;7:12859.
21. Viola JR, et al. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice. Circ Res. 2016;119(9):1030-1038.
22. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349-361.
23. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti-inflammatory- pro-resolving mediators and their receptors. Curr Top Med Chem. 2011;11(6):629-647.
24. Simiele F, et al. Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB J. 2012;26(3):1323-1333.
25. Fredman G, et al. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci U S A. 2014;111(40):14530-14535.
26. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852-1866.
27. Lin J, et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 2013;3(1):200-210.
28. Karunakaran D, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv. 2016;2(7):e1600224.
29. Kojima Y, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86-90.
30. Tibrewal N, et al. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-κB transcriptional activation. J Biol Chem. 2008;283(6):3618-3627.
31. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131(6):1124-1136.
32. Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, Henson PM. Apoptotic cells, through transforming growth factor-β, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem. 2006;281(50):38376-38384.
33. Li Y, Dalli J, Chiang N, Baron RM, Quintana C, Serhan CN. Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity. 2013;39(5):885-898.
34. Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol. 2005;6(12):1191-1197.
35. Scott RS, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 2001;411(6834):207-211.
36. Wu J, et al. Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis. Arthritis Res Ther. 2011;13(2):R62.
37. Zizzo G, Guerrieri J, Dittman LM, Merrill JT, Cohen PL. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther. 2013;15(6):R212.
38. Qin B, et al. The association of Tyro3/Axl/Mer signaling with inflammatory response, disease activity in patients with primary Sjögren's syndrome. Joint Bone Spine. 2015;82(4):258-263.